Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 12,214	$ 7,704
General and administrative	3,700	2,514
Total operating expenses	15,914	10,218
Operating loss	(15,914)	(10,218)
Non-operating income (expense):
Interest and other income, net	1,404	400
Loss from change in fair value of derivative liability	(14)	(13)
Total non-operating income, net	1,390	387
Net loss	(14,524)	(9,831)
Other comprehensive income:
Net unrealized gain on available-for-sale marketable debt securities	67
Comprehensive loss	$ (14,457)	$ (9,831)
Net loss per common share - basic (in dollars per share)	$ (0.28)	$ (0.19)
Net loss per common share - diluted (in dollars per share)	$ (0.28)	$ (0.19)
Weighted average number of common shares outstanding - basic (in shares)	51,409	50,528
Weighted average number of common shares outstanding - diluted (in shares)	51,409	50,528